1Marin HK.Appropriate empirical antibacterial therapy for nosocomial infections[J].Drugs,2003,63(20):2157-2168.
2Kang CI,Kin SH,Kim HB,et al.Pseudomonas aeruginosa bacteremia:risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome[J].Clin Infect Dis,2003,37(23):745-751.
3American Thoracic Society.Guidelines for the management of adults with community acquired pneumonia[J].Am J Crit Care Med,2001,163 (7): 1730-1754.
4American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia[J].Am J Respir Crit Care,2005,171 (4):388-416.
5Martinez JA,Horcajada JP, Almela M,et al .Addition of amacrolide to a 6-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia[J].Clin Infect Dis,2003,36(4):389-395.
6Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Dis-eases Society of America/American Thoracic Society consen-sus guidelines on the man agement of community-acquiredpneumonia in adults[J].Clin Infect Dis,2007,44(Suppl 2):S27-S72.
